Search for a command to run...
Mark Zuckerberg and Priscilla Chan discuss their Chan Zuckerberg Initiative's vision to revolutionize biology through AI, focusing on building frontier biology and AI labs that work together to create virtual cell models, advance precision medicine, and potentially cure or prevent all diseases.
Andrew White shares his journey from academia to founding Future House and Edison Scientific, discussing how AI can automate scientific discovery by creating world models, generating and filtering hypotheses, and iterating through experimental loops with the goal of accelerating scientific research across domains.
Nick Allardice discusses how GiveDirectly uses AI, mobile technology, and satellite imagery to quickly provide direct cash transfers to vulnerable populations during disasters and poverty, leveraging innovative approaches like anticipatory action and precise targeting to help people most in need.
Jennifer Doudna, Nobel Prize-winning biochemist, discusses the present and future of CRISPR gene editing technologies, highlighting breakthrough therapies for sickle cell disease and rare genetic disorders, while exploring potential applications in agriculture, preventive medicine, and the intersection of CRISPR with AI.
Seb and Preston explore the rapid evolution of AI, delving into tools like Claude Co-Work, breakthrough technologies, potential societal transformations, and emerging innovations in computation, blockchain, and longevity science.
Zipline's CEO Keller Rinaudo Cliffton discusses the company's massive $625 million funding round, rapid U.S. expansion, and mission to revolutionize logistics through autonomous drone delivery, already serving over 5,000 hospitals and saving approximately 17,000 lives annually.
A mind-bending exploration of bioelectricity, cellular intelligence, and cognition, revealing how cells have memory, goal-directed behaviors, and the potential to reprogram biological systems beyond DNA's constraints.
Ray Kurzweil discusses the imminent technological singularity, predicting human-level AI by 2029, a thousand-fold increase in intelligence by 2045, and the transformative potential of AI, robotics, and human-machine merging.
A deep dive into the remarkable GLP-1 drugs that seem to help with weight loss, diabetes, addiction, neurological conditions, and more, exploring their mysterious mechanisms of moderation and potential future developments.
A deep dive into the rise of food allergies, the invention of the EpiPen, and how well-intentioned medical recommendations may have inadvertently caused millions of children to develop food allergies.
Josh Meier and Jack Dent from Chai Discovery discuss how their AI models are revolutionizing drug discovery by rapidly designing novel antibodies with promising drug-like properties, potentially transforming the biotech industry's approach to developing new therapies.
A discussion of cutting-edge technologies including personalized genetic health analysis, Google's space-based data centers, AI-powered education, haptic touch robotics, and philosophical questions about AI, simulations, and humanity's technological evolution.
Jake Becraft describes how Strand Therapeutics is developing programmable mRNA technology to create targeted cancer treatments that activate the immune system to selectively attack tumor cells, potentially transforming cancer from a fatal disease to a manageable condition.
In a candid conversation with cardiologist Eric Topol, Adam Grant explores cutting-edge insights on longevity, debunking health myths, preventing major diseases, and the potential of AI in transforming medical care.
Damien Fitzpatrick transformed his professional rugby career challenges into Pillar Performance, a multimillion-dollar supplement brand that solves performance and recovery needs through scientifically-formulated, TGA-listed products targeted at endurance athletes.
Julia DeWahl shares the story of Antares, a startup developing small nuclear micro-reactors for the US military and critical infrastructure, discussing the regulatory shifts, market potential, and vision for resilient, clean energy solutions.
A deeply personal account of using AI to navigate a son's rapid cancer diagnosis, treatment, and potential future scenarios, revealing AI's transformative potential as a medical advisor and information processor during a critical health crisis.
Two venture capitalists explore the brutal economics of biotech, revealing why the industry is struggling despite scientific advances, and how new modalities, AI, and a focus on invention could revive innovation in drug development.
In this episode, Sajith Wickramasekara, CEO of Benchling, discusses how AI can accelerate drug discovery, reduce development costs, and transform the biotech industry by making scientific research more efficient and data-driven.
Kyle Vogt discusses the exciting advancements in robotics, particularly home robots, highlighting how AI and machine learning are enabling more capable and specialized robots that could soon perform tasks like picking up toys, loading dishwashers, and potentially cooking steaks within the next five years.
Nicolai Tangen interviews Ester Baiget, CEO of Novonesis, about how the company uses fermentation and biotechnology to create natural, sustainable alternatives to chemicals in industries ranging from food and dairy to detergents and biofuels.
In this special GTC edition podcast episode, scientists and technology leaders explore how AI is transforming scientific discovery, accelerating research across fields from drug development to quantum computing, and potentially revolutionizing our understanding of molecular design, human biology, and complex systems.
Dr. David Fajgenbaum shares his personal journey of surviving Castleman's disease by discovering a repurposed drug (sirolimus) and now leads a nonprofit called Every Cure, which uses artificial intelligence to systematically search for new uses of existing FDA-approved drugs to treat diseases that currently lack effective treatments.
Joel Kocher, CEO of Humann, shares his journey of discovering nitric oxide, building a $200M company focused on cardiovascular health, and revealing the importance of adaptability, talent acquisition, and doing things right over doing them quickly.
Mel Robbins sits down with Mayo Clinic physician and cancer survivor Dr. Dawn Mussallem to explore five cancer-fighting foods and lifestyle changes that can heal your body and prevent disease.
A groundbreaking AI approach using small convolutional graph neural networks and modest computational resources successfully discovered novel antibiotics that can target drug-resistant bacteria through previously unknown mechanisms.
CytoReason is developing an AI-driven disease modeling platform that helps pharmaceutical companies make data-driven decisions throughout drug discovery by integrating and analyzing vast amounts of molecular data and scientific literature.
A deep dive into the groundbreaking gene therapy treatment of baby KJ, who was born with a rare genetic disorder, highlighting the potential of personalized genetic editing to treat previously untreatable conditions.
In a conversation with Stanford Medical School Dean Lloyd Minor, Derek Thompson explores the current capabilities and limitations of AI in medicine, examining its potential to diagnose diseases, design drugs, accelerate clinical trials, and help manage chronic illness.
An in-depth exploration of artificial intelligence's potential to revolutionize medicine, examining its capabilities and limitations in diagnosing diseases, drug discovery, clinical trials, and health monitoring.
Liam Fedus and Ekin Dogus Cubuk discuss their startup Periodic Labs, which aims to train AI systems to accelerate scientific discovery by using physical experiments as a reinforcement learning signal, with a focus on discovering high-temperature superconductors.
E11 Bio develops a novel technique using color barcodes and expansion microscopy to map brain circuits more accurately and potentially reduce the cost of creating a complete brain connectome.
Periodic Labs, co-founded by ChatGPT creator and former DeepMind physicist, is building an AI physicist to accelerate scientific discovery by combining large language models, simulations, and experimental data to tackle challenges like high-temperature superconductivity.
A comprehensive exploration of America's scientific challenges, highlighting NIH's new $50 million autism initiative, potential breakthroughs in drug research, and the critical need to rebuild public trust in science through rigorous, transparent research and humble communication.
OpenEvidence is revolutionizing clinical decision support for physicians by providing a semantic search platform that helps doctors quickly find precise, evidence-based medical information. The company has rapidly become the primary operating system for clinical knowledge, used by 40% of doctors in the United States and providing crucial support in navigating the exponentially growing complexity of medical research.
Two pioneering neurotechnology experts discuss brain computer interfaces (BCIs) that can decode brain signals non-invasively, with potential applications ranging from helping paralyzed patients communicate to understanding consciousness states like comas. The podcast explores how these advanced BCIs could revolutionize interactions between human brains and digital technologies, offering glimpses into future medical treatments and potentially merging human cognition with artificial intelligence.
Cathy Tie, a young biotech entrepreneur, discusses her new startup Manhattan Project, which aims to use gene editing on embryos to eliminate genetic diseases. In a wide-ranging conversation, she explores the ethical, scientific, and personal dimensions of germline gene editing, challenging conservative biotech norms and advocating for responsible technological advancement.